BioNTech to boost vaccine capacity to beat new strain
BioNTech to boost vaccine capacity to beat new strain
Share:

According to the German firm’s chief executive officer, Pfizer Inc. partner BioNTech SE is going to pursue all its options to increase the number of Covid-19 vaccine doses, than the 1.3 billion the companies have promised to produce next year. The companies will probably know by coming months whether and how many more doses to be produced, Ugur Sahin said late Monday during an interview. 

He further said, “I am confident that we will be able to increase our network capacity, but we don’t have numbers yet.” According to Bloomberg, in 6 countries, more than 2 million people have already received their first shot of the standard two-dose vaccine. Sahin further said that the vaccine firm BioNTech is seeking more raw materials it needs for its mRNA vaccine, more clean rooms and more cooperation partners.

Pfizer is producing vaccine at three locations in the US and one in Europe. While on the other hand, BioNTech has two manufacturing sites in Germany. The vaccine’s EU approval and an inoculation campaign is about to start on 27th December. The company said during a press conference on Tuesday that BioNTech expects to ship 12.5 million doses to Europe and 20 million to the US by the end of 2020. The partners have already begun shipping shots to the UK, where Health Secretary Matt Hancock on Monday tweeted that some 500,000 people received their first dose.

Also Read-

One in every 33 seconds a person died last week in US, Covid 19

Pope to read his Christmas message from inside the Vatican

Immigrant Covid 19 warriors in France to be awarded with French Citizenship, Salute

Join NewsTrack Whatsapp group
Related News